Trials / Completed
CompletedNCT04791332
A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants
A Double-blind, Placebo-controlled, Randomized, Single Ascending and Multiple Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Healthy Japanese Adult Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- Male
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) after single- and multiple-dose oral administration of JNJ-67953964 in healthy Japanese adult male participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-67953964 | JNJ-67953964 capsule will be administered orally. |
| DRUG | Placebo | Matching placebo will be administered orally. |
Timeline
- Start date
- 2021-04-30
- Primary completion
- 2021-07-28
- Completion
- 2021-07-28
- First posted
- 2021-03-10
- Last updated
- 2025-04-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04791332. Inclusion in this directory is not an endorsement.